THCA-C4 (Delta-9-Tetrahydrocannabinolic Acid C4)

When Italian researchers formally isolated delta-9-tetrahydrocannabutol (THC-C4 / Δ9-THCB) from the FM2 cannabis strain in 2020, the finding turned heads: a cannabinoid with a four-carbon side chain binding CB1 receptors with affinity (Ki = 15 nM) comparable to or greater than standard delta-9-THC (Linciano et al., 2020). What that paper also implied — but did not extensively investigate — was the existence of its raw plant precursor: THCA-C4, the acidic butyl-chain form.

This post covers THCA-C4 as a standalone compound: what is structurally confirmed, how it relates to its neutral form, what its microbial biosynthetic origin suggests, and why its independent pharmacology remains uncharacterized.

What Is THCA-C4?

Delta-9-tetrahydrocannabinolic acid C4 (THCA-C4) is the carboxylic acid precursor to Δ9-tetrahydrocannabutol (THC-C4, also known as Δ9-THCB or butyl-THC). It has the same four-carbon (butyl) alkyl side chain at the resorcinol ring position as THC-C4, plus the –COOH (carboxylic acid) group that defines the raw, unheated form of all phytocannabinoid acids. Its molecular formula is C₂₁H₂₈O₄, and it is catalogued in cannabinoid databases with PubChem CID 59444388 (Green CulturED, 2025; America’s Best Buds, 2024).

THCA-C4 is structurally analogous to THCA (THCA-C5) but with one fewer carbon in the side chain — butyl (C4) instead of pentyl (C5). It decarboxylates to THC-C4 in exactly the same way that THCA decarboxylates to Δ9-THC: lose the –COOH as CO₂ under heat, yield the pharmacologically active neutral compound.

The Relationship to THC-C4 (Δ9-THCB)

THCA-C4’s pharmacological significance is largely defined by what it becomes. Its neutral form, THC-C4 (Δ9-THCB), was formally isolated and characterized in the Linciano et al. (2020) study published in the Journal of Natural Products. The key finding: Δ9-THCB demonstrated CB1 receptor affinity with a Ki of 15 nM — significantly stronger than standard Δ9-THC’s ~40 nM, despite having a shorter side chain. This counterintuitive result (shorter chain, stronger binding) challenged the simple linear SAR model and established the butyl cannabinoid series as scientifically important (Linciano et al., 2020).

THCA-C4 is to THC-C4 as THCA is to Δ9-THC, or as CBDA is to CBD: the raw acid form present in the living, unheated plant, which converts upon decarboxylation to the pharmacologically characterized neutral compound. This makes THCA-C4 the form you would actually encounter in raw cannabis tissue, before any heat processing occurs.

Biosynthetic Origin: Microbial, Not Enzymatic

A key distinction between THCA-C4 and standard THCA-C5 is their likely biosynthetic routes. THCA-C5 is produced by THCA synthase — a well-characterized plant enzyme that converts CBGA (cannabigerolic acid) to THCA. No equivalent enzyme specifically producing butyl-chain cannabinoids has been identified in cannabis (Linciano et al., 2020).

Instead, the prevailing hypothesis is that THCA-C4 (and its CBD-family counterpart CBDA-C4/CBDB) arises from microbial ω-oxidation and decarboxylation of their five-carbon C5 counterparts — a biotransformation carried out by microorganisms associated with the cannabis plant rather than by plant enzymes directly. This means THCA-C4 is not a primary biosynthetic product but rather a secondary compound produced through microbial metabolism of THCA-C5 (Linciano et al., 2020; ScienceDirect, 2024).

This distinction is practically important: it explains why THCA-C4 is found in only trace quantities (dependent on the microbial activity present in a given plant/environment), why it was not identified until modern sensitive analytical methods became available, and why it cannot simply be bred into higher concentrations by selecting for THCA synthase expression.

Context: The Butyl Cannabinoid Series

THCA-C4 is part of the broader butyl phytocannabinoid series that was being characterized in the years around Linciano et al.’s 2020 paper. This series includes:

THCA-C4’s Own Pharmacological Profile: An Open Question

No dedicated pharmacological studies on THCA-C4 as an independent compound have been published. What is known comes entirely from structural inference and analogy:

In raw acid form, THCA-C4 is non-psychoactive — the carboxylic acid group prevents CB1 receptor binding in the same way THCA-C5 is non-psychoactive despite its high neutral-form potency. Whether THCA-C4 possesses THCA-C5-type independent activities — such as PPARγ agonism, COX inhibition, or TRP channel modulation — is completely unknown. The positional equivalence suggests it might, but the one-carbon chain difference could produce meaningful differences in target engagement that have simply never been tested (America’s Best Buds, 2024; Green CulturED, 2025).

Frequently Asked Questions

The Bottom Line

THCA-C4 is the raw plant form of one of the more pharmacologically surprising recent cannabinoid discoveries — THC-C4, whose unexpectedly high CB1 receptor affinity challenged the linear side-chain SAR model. As the acid precursor, THCA-C4 is the form present in unheated cannabis tissue, arising from microbial transformation rather than direct plant enzymatic biosynthesis.

Its independent pharmacological profile is an open question — no dedicated research has been conducted on the acid form as a distinct compound. Its significance today is primarily structural: it completes the butyl cannabinoid series and represents the gateway form through which the pharmacologically active THC-C4 is produced in the plant. Whether THCA-C4 has therapeutic properties of its own, analogous to THCA-C5’s PPARγ activity and neuroprotective effects, remains to be discovered.

Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.

Back to List of Cannabinoids